According to FutureWise analysis the market for gonorrhea therapeutics in 2023 was US$ 1.7 billion, and is expected to reach US$ 2.5 billion by 2031 at a CAGR of 5.3%.
The bacterium *Neisseria gonorrhoeae* is responsible for the sexually transmitted disease gonorrhea. This infection commonly affects warm, moist areas of the body, including the urethra, eyes, throat, vagina, anus, and female reproductive tract. Gonorrhea is primarily transmitted through unprotected sexual intercourse. If a mother is infected, she can also pass the infection to her baby during delivery. Symptoms typically appear between two to fourteen days after exposure; however, some individuals may not exhibit any noticeable symptoms at all. Those without symptoms are at a higher risk of transmitting the infection to others. Due to its ability to quickly develop resistance to various antibiotic classes, gonococcal infections have become a significant global health concern. Over time, the effectiveness of antibiotics such as sulfonamides, penicillin, tetracyclines, and fluoroquinolones has diminished against *N. gonorrhoeae*. Currently, cephalosporins are the first-line treatment, but there have recently been reported cases of resistance to these drugs as well.
In women, gonorrhea often goes unnoticed, while men are more likely to show symptoms. When symptoms do occur in women, they may include vaginal discharge, painful urination (dysuria), painful intercourse (dyspareunia), abnormal uterine bleeding, lower abdominal pain, and irritation in the rectal area. In men, symptoms may present as testicular or rectal pain, dysuria, and discharge or itching from the urethra. The urethra and cervix are the most commonly affected areas, followed by the anal and pharyngeal regions. During the initial clinical visit, healthcare providers typically initiate empiric therapy for gonococcal infections based on the patient’s history, such as engaging in sexual activity with someone who has a sexually transmitted infection (STI), or on the presence of clinical symptoms, such as penile discharge or abnormal vaginal discharge.
The bacteria Neisseria gonorrhoeae is the prevalent sexually transmitted illness known as gonorrhea. Both men and women can be affected by the condition, which if untreated, can cause major health issues like infertility and an elevated risk of HIV transmission. Due to growing gonorrhea prevalence and increased public awareness of the condition, the worldwide market for gonorrhea therapeutics has seen rapid expansion in recent years. A number of reasons, including the availability of efficient medications, rising healthcare costs, and growing disease awareness, are driving the gonorrhea therapeutics market.
Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=9153%20&type=requestsample
Gonorrhea Therapeutics Market Segmentation:
By Gonococcal Infection
- Uncomplicated Gonococcal Infection
- Gonococcal Arthritis
- Gonococcal Meningitis and Endocarditis
By Treatment
- Monotherapy
- Dual Therapy
By Route of Administration
- Oral
- Injectable
By Gender
- Women
- Men
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in Gonorrhea Therapeutics Market:
- Hologic, Inc.
- Merck & Co.
- Pfizer Inc.
- AstraZeneca
- Danaher
- Abbott
- Becton Dickinson and Company
- F. Hoffmann-La Roche Ltd.
- Lupin Pharmaceuticals
- Teligent, Inc.
- Bayer AG
- GlaxoSmithKline Plc.
- Novartis AG.
- Allergan plc
- Sanofi S.A.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Baxter International Inc.
Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=9153&license=multi
**Objectives of this Study: **
- To provide a comprehensive analysis of the Gonorrhea Therapeutics Market By Gonococcal Infection, By Treatment, By Route of Administration, By Gender, By Distribution Channel and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com
